Table 1.
Therapeutic agents targeting angiogenesis in interventional phase 3 and 4 clinical trials currently recruiting or not yet recruiting. Data acquired from the U.S. National library of medicine (http://clinicaltrials.gov, accessed on 18 January 2019).
| VEGF 1/VEGFR 2 Targeting Therapeutic Agent | Therapeutic Strategy | Cancer Type | Clinical Trial Reference (Phase) |
|---|---|---|---|
| Bevacizumab (Apatinib) | Bevacizumab (anti-VEGF) in a chemotherapeutic cocktail with 5-Fu, Folinic acid, Panitumumab and intra-arterial vs. intravenous Oxaliplatin | Colorectal neoplasms | NCT02885753 (3) |
| Cisplatin with Etoposide vs. Cisplatin, Etoposide and Bevacizumab | Small cell lung cancer | NCT03100955 (3) | |
| Bevacizumab vs. placebo | Thyroid cancer | NCT03048877 (3) | |
| Bevacizumab as second line treatment | Intrahepatic Cholangiocarcinoma | NCT03251443 (3) | |
| LY01008 and Bevacizumab | LY01008 (anti-VEGF antibody) with Carboplatin/Paclitaxel vs. Bevacizumab with Carboplatin/Paclitaxel | Non-small cell lung cancer | NCT03533127 (3) |
| Cediranib | Olaparib (PARP inhibitor) with Cediranib (VEGF-A inhibitor) or Olaparib alone | Ovarian cancer | NCT03278717 (3) |
| Ramucirumab (LY3009806) | Ramucirumab (anti-VEGFR) with Paclitaxel vs. Placebo with Paclitaxel | Gastric adenocarcinoma | NCT02898077 (3) |
| Aflibercept | Injection of Aflibercept (anti-VEGF) vs. placebo injection | Ocular melanoma | NCT03172299 (3) |
| Everolimus (RAD001) | Everolimus (m-TOR inhibitor) alone | Renal cell carcinoma | NCT01206764 (4) |
1 VEGF, Vascular endothelial growth factor; 2 VEGFR, Vascular endothelial growth factor receptor